Robert G Bristow
Overview
Explore the profile of Robert G Bristow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
9489
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hawley J, Zhou S, Arlidge C, Grillo G, Kron K, Hugh-White R, et al.
Cancer Res
. 2021 Oct;
81(23):5833-5848.
PMID: 34642184
Prostate cancer is a heterogeneous disease whose progression is linked to genome instability. However, the impact of this instability on the noncoding genome and its three-dimensional organization to aid progression...
22.
Ramotar M, Chua M, Truong H, Hosni A, Pintilie M, Davicioni E, et al.
Urol Oncol
. 2021 Sep;
40(1):5.e1-5.e13.
PMID: 34538726
Purpose/objective: Risk-stratification for post-prostatectomy radiotherapy (PORT) using conventional clinicopathologic indexes leads to substantial over- and under-treatment. Better patient selection could spare unnecessary toxicities and improve outcomes. We investigated the prognostic...
23.
Sandhu S, Moore C, Chiong E, Beltran H, Bristow R, Williams S
Lancet
. 2021 Aug;
398(10305):1075-1090.
PMID: 34370973
The management of prostate cancer continues to evolve rapidly, with substantial advances being made in understanding the genomic landscape and biology underpinning both primary and metastatic prostate cancer. Similarly, the...
24.
Bibby B, Thiruthaneeswaran N, Yang L, Pereira R, More E, McArt D, et al.
BMC Urol
. 2021 Jul;
21(1):96.
PMID: 34210300
Background: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the...
25.
Thiruthaneeswaran N, Bibby B, Yang L, Hoskin P, Bristow R, Choudhury A, et al.
Eur J Cancer
. 2021 Mar;
148:260-276.
PMID: 33756422
The history of radiotherapy is intertwined with research on hypoxia. There is level 1a evidence that giving hypoxia-targeting treatments with radiotherapy improves locoregional control and survival without compromising late side-effects....
26.
Glicksman R, Metser U, Vines D, Valliant J, Liu Z, Chung P, et al.
Eur Urol
. 2021 Mar;
80(3):374-382.
PMID: 33685838
Background: The hypothesis of a curable oligometastatic prostate cancer (PCa) state remains to be clinically-proven. Conventional imaging often fails to localize early recurrences, hampering the potential for radical approaches. Objective:...
27.
Rebello R, Oing C, Knudsen K, Loeb S, Johnson D, Reiter R, et al.
Nat Rev Dis Primers
. 2021 Feb;
7(1):9.
PMID: 33542230
Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of...
28.
Barriuso J, Nagaraju R, Belgamwar S, Chakrabarty B, Burghel G, Schlecht H, et al.
Clin Cancer Res
. 2020 Dec;
27(4):1119-1130.
PMID: 33257424
Purpose: At diagnosis, colorectal cancer presents with synchronous peritoneal metastasis in up to 10% of patients. The peritoneum is poorly characterized with respect to its superspecialized microenvironment. Our aim was...
29.
Rubin M, Bristow R, Thienger P, Dive C, Imielinski M
Mol Cell
. 2020 Nov;
80(4):562-577.
PMID: 33217316
Intratumoral heterogeneity can occur via phenotype transitions, often after chronic exposure to targeted anticancer agents. This process, termed lineage plasticity, is associated with acquired independence to an initial oncogenic driver,...
30.
Mahmood S, Bollipo S, Steele S, Bristow R, Choudhury A, Oakland K, et al.
Gastroenterology
. 2020 Oct;
160(3):635-638.
PMID: 33096102
No abstract available.